PROCEPT BioRobotics investors face Sept. 22 deadline in securities case
A law firm says investors who lost money in PROCEPT BioRobotics Corp. stock may seek to lead a securities fraud class action tied to alleged misleading statements about sales and inventory.
A PR Newswire notice from Glancy Prongay Wolke & Rotter LLP says investors who lost money in PROCEPT BioRobotics Corporation shares may seek to serve as lead plaintiff in a securities fraud class action.
The notice sets a Sept. 22, 2026, deadline for investors who want to ask the court to lead the case. The release says no class has been certified yet.
According to the press release, the complaint covers alleged misconduct from Feb. 28, 2024, through Feb. 25, 2026. It says the claims center on alleged false or misleading statements about PROCEPT’s business, operations and financial condition.
The release alleges the company failed to disclose an extensive discount program that encouraged customers to place bulk handpiece orders above procedure demand. It says the program artificially and unsustainably inflated reported U.S. handpiece unit sales and revenues by pulling forward sales from later periods.
The notice also says customer handpiece orders exceeded underlying procedure demand throughout the class period and that the gap widened over time. By the end of the period, it says, the result was more than 10,000 excess units of field inventory.
Glancy Prongay Wolke & Rotter LLP said the alleged effect was that PROCEPT overstated handpiece sales and the utilization of its field systems, while leaving investors exposed to undisclosed operational and financial harm. The release was dated Aug. 4, 2026, and identified PROCEPT BioRobotics Corporation by ticker PRCT.
The notice gives contact details for investors who want more information. It lists an email address, a phone number and a toll-free number for the firm.
What happens next depends on whether an investor moves the court by the Sept. 22 deadline. The release says the class action remains uncertified.
Sources
Editorial note: This article was prepared with AI assistance and includes source attribution for reader review.
View the Web StoryA visual, tap-through version of this reportThis is the AMP version of the article. Read the full article on Atlas Watchline.